Company Overview
| Stock Name | Yonghe Medical |
|---|---|
| Stock Code | 02279 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是中國領先的專門從事提供毛髮醫療服務的醫療集團,提供一站式毛髮醫療服務,涵蓋植髮醫療、醫療養固、常規養護及其他配套服務。 |
| Listing Date | 2021-12-13 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市朝陽區甘露園南里20號中國核建大廈11層 |
| Business Address (Hong Kong) | 香港皇后大道東183號合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.yonghegroup.cn |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 15.80 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 7,900 |
| Par Value | To be extracted |
| Offer Period | 2021-12-01 to 2021-12-06 |
| Global Offering Shares | 94,424,000 shares |
| HK Public Offer Shares (Initial) | 9,443,000 shares (10.0%) |
| Public Offer Lots (Initial) | 18,886lots (Pool A9,443lots,Pool B9,443lots) |
| International Placing Shares (Initial) | 84,981,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 519,955,916 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 50.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,491,899,200 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 7,900 |
| 2 lots | 1,000 | HK$ 15,800 |
| 3 lots | 1,500 | HK$ 23,700 |
| 4 lots | 2,000 | HK$ 31,600 |
| 5 lots | 2,500 | HK$ 39,500 |
| 6 lots | 3,000 | HK$ 47,400 |
| 7 lots | 3,500 | HK$ 55,300 |
| 8 lots | 4,000 | HK$ 63,200 |
| 9 lots | 4,500 | HK$ 71,100 |
| 10 lots | 5,000 | HK$ 79,000 |
| 12 lots | 6,000 | HK$ 94,800 |
| 14 lots | 7,000 | HK$ 110,600 |
| 16 lots | 8,000 | HK$ 126,400 |
| 18 lots | 9,000 | HK$ 142,200 |
| 20 lots | 10,000 | HK$ 158,000 |
| 30 lots | 15,000 | HK$ 237,000 |
| 40 lots | 20,000 | HK$ 316,000 |
| 50 lots | 25,000 | HK$ 395,000 |
| 60 lots | 30,000 | HK$ 474,000 |
| 70 lots | 35,000 | HK$ 553,000 |
| 80 lots | 40,000 | HK$ 632,000 |
| 90 lots | 45,000 | HK$ 711,000 |
| 100 lots | 50,000 | HK$ 790,000 |
| 120 lots | 60,000 | HK$ 948,000 |
| 140 lots | 70,000 | HK$ 1,106,000 |
| 160 lots | 80,000 | HK$ 1,264,000 |
| 180 lots | 90,000 | HK$ 1,422,000 |
| 200 lots | 100,000 | HK$ 1,580,000 |
| 400 lots | 200,000 | HK$ 3,160,000 |
| 600 lots | 300,000 | HK$ 4,740,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 800 lots | 400,000 | HK$ 6,320,000 |
| 1,000 lots | 500,000 | HK$ 7,900,000 |
| 1,200 lots | 600,000 | HK$ 9,480,000 |
| 1,400 lots | 700,000 | HK$ 11,060,000 |
| 1,600 lots | 800,000 | HK$ 12,640,000 |
| 1,800 lots | 900,000 | HK$ 14,220,000 |
| 2,000 lots | 1,000,000 | HK$ 15,800,000 |
| 4,000 lots | 2,000,000 | HK$ 31,600,000 |
| 6,000 lots | 3,000,000 | HK$ 47,400,000 |
| 8,000 lots | 4,000,000 | HK$ 63,200,000 |
| 9,443 lots | 4,721,500 | HK$ 74,599,700 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 1.09B |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +794% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 8,215,303,472 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣163.3百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2018 | 2019 | 2020 |
|---|---|---|---|
| Revenue | 934,326 | 1,224,477 | 1,638,297 |
| Cost of sales | -232,207 | -335,379 | -416,667 |
| Gross profit | 702,119 | 889,098 | 1,221,630 |
| Other income and gains, net | 933 | 1,443 | 6,304 |
| Selling and distribution expenses | -463,681 | -650,262 | -779,611 |
| Administrative expenses | -93,952 | -129,962 | -162,022 |
| Operating profit | 128,958 | 98,041 | 266,261 |
| Net finance costs | -17,669 | -26,518 | -35,347 |
| Profit before tax | 111,289 | 71,523 | 230,914 |
| Income tax expense | -57,789 | -35,899 | -67,582 |
| Profit for the year | 53,500 | 35,624 | 163,332 |
| Profit attributable to owners | 53,500 | 35,624 | 163,332 |
Balance Sheet
| Item | 2018 | 2019 | 2020 | 2021-06 |
|---|---|---|---|---|
| Cash and cash equivalents | 68,476 | 89,789 | 292,856 | |
| Trade and bills receivables | 9,805 | 5,859 | 10,330 | |
| Inventories | 14,255 | 14,486 | 26,996 | |
| Total current assets | 152,647 | 178,433 | 437,612 | |
| Total assets | 734,445 | 931,213 | 1,594,356 | |
| Total current liabilities | 205,223 | 280,728 | 505,200 | |
| Total liabilities | 530,949 | 692,093 | 1,188,298 | |
| Total equity | 203,496 | 239,120 | 406,058 | |
| Equity attributable to owners | 203,496 | 239,120 | 406,058 | |
| Interest-bearing borrowings | 0 | 44,827 | 25,870 | 214,395 |
Cash Flow Statement
| Item | 2018 | 2019 | 2020 | 2021-06 |
|---|---|---|---|---|
| Net cash from operating activities | 194,567 | 182,480 | 501,571 | |
| Net cash from investing activities | -102,789 | -105,352 | -142,388 | |
| Net cash from financing activities | -69,689 | -55,815 | -156,116 | |
| Net increase in cash | 22,089 | 21,313 | 203,067 | |
| Purchase of PP&E | -135,424 | -105,808 | -142,204 | -92,462 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 16.6 |
|---|---|
| First Day Open | HK$ 15.76 |
| First Day Change | -85.44% |
| First Day Volume | 61374600.0 |
| First Day Turnover | 1026880000.0 |
| Use of Proceeds | 1、約42.1%或571.2百萬港元將用于為我們在中國境內網絡的現有植發醫療機構進行擴充和升級;
2、約17.5%或237.4百萬港元將用于為我們的產品及服務項目創新撥資;
3、約9.7%或131.6百萬港元將用作投資于研發,及以前沿技術提升我們的服務體系;
4、約23.4%或317.5百萬港元將用作在中國整合行業資源以提升我們的品牌知名度;
5、約1.6%或21.7百萬港元將用作結清我們就于2021年5月收購顯赫植發應付關聯方新絲域的并購代價之未償還結余;
6、約5.7%或77.3百萬港元將用作我們的營運資金及一般企業用途。 |
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (2)
Joint Bookrunners (2)
Joint Lead Managers (2)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Athos Asia Event Driven Master Fund | 38,457,200 HKD | — | 2.58% | — | 6 months | 2022-06-13 |
| 2 | Enreal China Master Fund | 76,898,600 HKD | — | 5.15% | — | 6 months | 2022-06-13 |
| 3 | Hudson Bay Master Fund LTD | 76,898,600 HKD | — | 5.15% | — | 6 months | 2022-06-13 |
| 4 | Lake Bleu Prime Healthcare Master Fund Limited | 76,898,600 HKD | — | 5.15% | — | 6 months | 2022-06-13 |
| 5 | LAV Star Limited | 76,898,600 HKD | — | 5.15% | — | 6 months | 2022-06-13 |
| 6 | NCC China A-Share Master Fund | 153,805,100 HKD | — | 10.31% | — | 6 months | 2022-06-13 |
| 7 | WT Asset Management Limited | 76,898,600 HKD | — | 5.15% | — | 6 months | 2022-06-13 |
| 8 | Yi Fang Da Hadar Investment Limited | 76,898,600 HKD | — | 5.15% | — | 6 months | 2022-06-13 |
| 9 | York Asian Opportunities Investments Master Fund, LP | 38,457,200 HKD | — | 2.58% | — | 6 months | 2022-06-13 |
| 10 | 常春藤资产管理(香港)有限公司 | 53,838,500 HKD | — | 3.61% | — | 6 months | 2022-06-13 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 張玉 | — |
| Company Secretary | 韓志梅、梁晶晶 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 張先生透過ZY Investment Capital Ltd及上海予諾科技控股有限公司持有約34.91%權益;Yonghe Hair Service及CYH共同控制約35.34%權益;ZH Investment Capital Ltd持有約4.62%權益。 |
|---|




